Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Net Income towards Common Stockholders: 2019-2024

Historic Net Income towards Common Stockholders for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to -$187.4 million.

  • Keros Therapeutics' Net Income towards Common Stockholders rose 86.25% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 135.50%. This contributed to the annual value of -$187.4 million for FY2024, which is 22.46% down from last year.
  • Keros Therapeutics' Net Income towards Common Stockholders amounted to -$187.4 million in FY2024, which was down 22.46% from -$153.0 million recorded in FY2023.
  • Keros Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$45.4 million during FY2020, with a 5-year trough of -$187.4 million in FY2024.
  • For the 3-year period, Keros Therapeutics' Net Income towards Common Stockholders averaged around -$148.3 million, with its median value being -$153.0 million (2023).
  • Data for Keros Therapeutics' Net Income towards Common Stockholders shows a maximum YoY tumbled of 220.89% (in 2020) over the last 5 years.
  • Keros Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$45.4 million in 2020, then decreased by 29.50% to -$58.7 million in 2021, then crashed by 78.20% to -$104.7 million in 2022, then crashed by 46.15% to -$153.0 million in 2023, then fell by 22.46% to -$187.4 million in 2024.